Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions
1 other identifier
observational
120
1 country
1
Brief Summary
Non-alcoholic fatty liver disease is the most common cause of chronic liver disease worldwide. It is defined as the accumulation of fat (\>5%) in the liver cells in the absence of excessive alcohol intake or other causes of liver disease including viral, drug-induced, or autoimmune. Non-alcoholic fatty liver disease is a hepatic manifestation of metabolic syndrome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 30, 2017
CompletedFirst Posted
Study publicly available on registry
June 1, 2017
CompletedStudy Start
First participant enrolled
July 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2018
CompletedAugust 16, 2017
August 1, 2017
1 year
May 30, 2017
August 13, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
The percentage of patients with abnormal laboratory glomerular filtration rate
decreased glomerular filtration rate \<60 mL/minute will be considered abnormal
1 day
Study Arms (2)
study group
non alcoholic fatty liver disease patients
Control group
fatty liver patients
Interventions
collection of blood sample 5 milliliter for calculation of glomerular filtration rate
Eligibility Criteria
Patients will be recruited outpatient clinic of internal medicine of Luxor international hospital and Assiut university hospital
You may qualify if:
- All non alcoholic fatty liver disease patients evidenced by abdominal ultrasound.
- Urine analysis whether normal or renal sedimentation.
You may not qualify if:
- Alcoholic fatty liver patients.
- patients known to have diabetes mellitus.
- patients with other causes of liver disease as viral hepatitis, drug induced,or autoimmune.
- patients known to have kidney disease.
- Hypertension.
- Hyperuricemia.
- Impaired urea and creatinine patients.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ahmed Abbas
Assiut, Cairo Governorate, 002, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principal investigator
Study Record Dates
First Submitted
May 30, 2017
First Posted
June 1, 2017
Study Start
July 1, 2017
Primary Completion
July 1, 2018
Study Completion
September 1, 2018
Last Updated
August 16, 2017
Record last verified: 2017-08
Data Sharing
- IPD Sharing
- Will not share